BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

912 related articles for article (PubMed ID: 35627236)

  • 1. A Novel Cuproptosis-Related Prognostic Gene Signature and Validation of Differential Expression in Clear Cell Renal Cell Carcinoma.
    Bian Z; Fan R; Xie L
    Genes (Basel); 2022 May; 13(5):. PubMed ID: 35627236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic, Clinicopathological, and Function of Key Cuproptosis Regulator
    Zeng S; Zhang H; Zhang D; Hu X; Song L
    Genes (Basel); 2022 Sep; 13(10):. PubMed ID: 36292610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cuproptosis-related gene
    Wang T; Liu Y; Li Q; Luo Y; Liu D; Li B
    Front Immunol; 2022; 13():999823. PubMed ID: 36225932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel cuproptosis-related gene signature of prognosis and immune microenvironment in head and neck squamous cell carcinoma cancer.
    Jiang X; Ke J; Jia L; An X; Ma H; Li Z; Yuan W
    J Cancer Res Clin Oncol; 2023 Jan; 149(1):203-218. PubMed ID: 36376617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction of cuproptosis signature based on bioinformatics and experimental validation in clear cell renal cell carcinoma.
    Tian X; Zhu S; Liu W; Wu X; Wei G; Zhang J; Anwaier A; Chen C; Ye S; Che X; Xu W; Qu Y; Zhang H; Ye D
    J Cancer Res Clin Oncol; 2023 Dec; 149(19):17451-17466. PubMed ID: 37889309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive investigation into cuproptosis in the characterization of clinical features, molecular characteristics, and immune situations of clear cell renal cell carcinoma.
    Wang B; Song Q; Wei Y; Wu X; Han T; Bu H; Tang S; Qian J; Shao P
    Front Immunol; 2022; 13():948042. PubMed ID: 36275737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and Validation of Cuproptosis-Related Prognostic Signature and Associated Regulatory Axis in Uterine Corpus Endometrial Carcinoma.
    Chen Y
    Front Genet; 2022; 13():912037. PubMed ID: 35937995
    [No Abstract]   [Full Text] [Related]  

  • 8. A novel cuproptosis-related prognostic gene signature in adrenocortical carcinoma.
    Gao W; He X; Huangfu Q; Xie Y; Chen K; Sun C; Wei J; Wang B
    J Clin Lab Anal; 2023 Nov; 37(21-22):e24981. PubMed ID: 37997497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cuproptosis-Related MiR-21-5p/FDX1 Axis in Clear Cell Renal Cell Carcinoma and Its Potential Impact on Tumor Microenvironment.
    Xie M; Cheng B; Yu S; He Y; Cao Y; Zhou T; Han K; Dai R; Wang R
    Cells; 2022 Dec; 12(1):. PubMed ID: 36611966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cuproptosis related gene PDHB is identified as a biomarker inversely associated with the progression of clear cell renal cell carcinoma.
    Wang H; Yang Z; He X; Guo F; Sun H; Xu S; Xu C; Wang Z; Wen H; Teng Z; Wang Y; Han Z
    BMC Cancer; 2023 Aug; 23(1):804. PubMed ID: 37641032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel cuproptosis-related gene prognostic signature in colon adenocarcinoma.
    Su Y; Zhang K
    Can J Physiol Pharmacol; 2023 Nov; 101(11):589-598. PubMed ID: 37698225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-omics pan-cancer study of cuproptosis core gene
    Xu J; Hu Z; Cao H; Zhang H; Luo P; Zhang J; Wang X; Cheng Q; Li J
    Front Immunol; 2022; 13():981764. PubMed ID: 36605188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel Cuproptosis-Related Prognostic Model and the Hub Gene
    Zhang K; Yang W; Zhang Z; Ma K; Li L; Xu Y; Qiu J; Yu C; Zhou J; Cai L; Gong Y; Gong K
    J Oncol; 2022; 2022():2124088. PubMed ID: 36536785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel prognostic signature of cuproptosis-related genes and the prognostic value of FDX1 in gliomas.
    Zhu H; Wan Q; Tan J; Ouyang H; Pan X; Li M; Zhao Y
    Front Genet; 2022; 13():992995. PubMed ID: 36579333
    [No Abstract]   [Full Text] [Related]  

  • 15. The cuproptosis-associated 13 gene signature as a robust predictor for outcome and response to immune- and targeted-therapies in clear cell renal cell carcinoma.
    Yuan H; Qin X; Wang J; Yang Q; Fan Y; Xu D
    Front Immunol; 2022; 13():971142. PubMed ID: 36131921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Confirmation of the predictive function of cuproptosis-related gene FDX1 in clear cell renal carcinoma using qRT-PCR and western blotting.
    Cai C; Zhou K; Jing J; Ren Y; Weng G; Cen D; Wang X; Huang S
    Aging (Albany NY); 2023 Jul; 15(13):6117-6134. PubMed ID: 37432054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cuproptosis related genes signature predicts the prognosis and correlates with the immune status of clear cell renal cell carcinoma.
    Sun P; Xu H; Zhu K; Li M; Han R; Shen J; Xia X; Chen X; Fei G; Zhou S; Wang R
    Front Genet; 2022; 13():1061382. PubMed ID: 36531222
    [No Abstract]   [Full Text] [Related]  

  • 18. A cuproptosis-related gene signature and associated regulatory axis in stomach adenocarcinoma based on bioinformatics analysis.
    Ding D; Wang D; Qin Y
    Medicine (Baltimore); 2023 Jul; 102(30):e34230. PubMed ID: 37505170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Database Mining Detected a Cuproptosis-Related Prognostic Signature and a Related Regulatory Axis in Breast Cancer.
    Jiang B; Zhu H; Feng W; Wan Z; Qi X; He R; Xie L; Li Y
    Dis Markers; 2022; 2022():9004830. PubMed ID: 36312586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cuproptosis-Related 4-Gene Risk Model for Predicting Immunotherapy Drug Response and Prognosis of Kidney Renal Clear Cell Carcinoma.
    Guo JS; Ding H; Wu PY; Xin ZY; Li JX; Jo HS; Ma ZH
    Chin Med Sci J; 2023 Sep; 38(3):191-205. PubMed ID: 37503721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.